FRANKFURT, GERMANY and PALO ALTO, Calif. , May 17, 2024
/PRNewswire/ -- Hypertension, or high blood pressure, affects one
in three Europeans over the age of 30 and more than one billion
people worldwide. Hypertension is known as the "silent
killer" because many people do not know they have it and, over
time, it can lead to serious health issues. Hypertension is the
number one contributor to the burden of human disease globally, has
been associated with a five-year reduction in life expectancy and
is a major risk factor for heart disease, stroke, heart attacks and
other serious health problems.
May 17 is World Hypertension Day,
a global initiative to highlight the importance of monitoring blood
pressure and provide education about this devastating chronic
disease. Recor Medical – the pioneer of the Paradise™
Ultrasound Renal Denervation (uRDN) System, a recently FDA-approved
medical device-based procedure to treat hypertension – is joining
the fight by promoting awareness and encouraging continued
innovation and equitable access to early intervention and
sustainable solutions for patients suffering from this chronic
disease.
According to a report from the World Health Organization,
the number of adults with hypertension doubled between 1990 and
2019 from 650 million to 1.3 billion. The report also states that
only 54 percent of adults with hypertension are diagnosed and only
42 percent receive treatment. Furthermore, left undetected or
uncontrolled, hypertension is a leading contributor to other
long-term risks, including:
- Chronic kidney disease or failure
- Vision loss
- Sexual dysfunction
- Dementia
- Uterine fibroids.
About one-third of the patients who are treated for hypertension
remain uncontrolled despite making healthy lifestyle changes and
taking more than three medications. For these patients, innovation
and investment in new solutions are vital to achieve blood pressure
control and realize a healthier future. From pharmaceutical
treatments to technology, patients need new therapies that can
provide life-changing results. This includes medical device-based
therapies, like the Paradise™ Ultrasound Renal Denervation (uRDN)
system, an additional treatment option for patients who remain
uncontrolled and at elevated cardiovascular risk despite standard
lifestyle changes and treatment with oral medications.
"While new technologies like Recor's Paradise uRDN system are
helping patients in the fight against hypertension and making a
significant impact on people's lives, we know education, early
intervention and hypertension management are critical first steps
to treating this chronic disease," said Lara Barghout, President and CEO of Recor
Medical. "We support the efforts of World Hypertension Day and will
continue to advocate with providers and for patients to mitigate
the effects of this disease before it progresses."
"Physicians and their patients who struggle with hypertension
are in need of innovative solutions. And, for those with
uncontrolled resistant hypertension, technology is becoming an
increasingly important option to help control this disease. All
interventions need to be considered to tackle this global problem,"
Barghout added.
Recor Medical's Paradise uRDN system is a first-of-its-kind
ultrasound-based renal denervation (RDN) technology designed to
lower blood pressure by denervating overactive sympathetic nerves
surrounding the renal arteries. Paradise uRDN delivers two to three
doses of 360-degree ultrasound energy — lasting seven seconds each
— through each of the main renal arteries to the surrounding
nerves. The Paradise catheter features the exclusive HydroCooling™
system, which circulates sterile water through the balloon during
the procedure to help cool and protect the inner layers of the
renal artery.
About Recor Medical, Inc.
Recor Medical, headquartered in Palo
Alto, Calif., a wholly owned subsidiary of Otsuka Medical
Devices Co., Ltd., is a medical technology company focused on
transforming the management of hypertension. Recor has pioneered
the use of the Paradise Ultrasound Renal Denervation system for the
treatment of hypertension. The Paradise system is an
investigational device in Japan,
is FDA approved in the United
States, and bears the CE mark. Recor has reported positive
outcomes in three independent, randomized, sham-controlled studies
of the Paradise system in patients with mild-to-moderate and
resistant hypertension. In addition, Recor has begun the Global
Paradise System ("GPS") Registry in the European Union and the UK,
with plans to expand globally.
http://www.recormedical.com/
About Otsuka Medical Devices
Otsuka Medical Devices Co., Ltd. engages in the global
development and commercialization of medical devices that provide
new therapeutic options in areas where patient needs cannot be met
through pharmaceutical or other conventional treatment. Otsuka
Medical Devices is a subsidiary of Otsuka Holdings Co., Ltd.
(www.otsuka.com/en), a global healthcare company listed on the
Tokyo Stock Exchange (JP 4578).
https://www.omd.otsuka.com/en/
The original press release can be seen at
www.recormedical.com
Media-Contact
Jennifer Disper-Wilmsen
Senior Manager Communications EMEA
Otsuka Medical Devices Europe GmbH (Recor Medical)
+49 (171) 17 68 49 0
Jennifer.Disper-Wilmsen@recormedical.com
Photo:
https://mma.prnewswire.com/media/2415365/Recor_Medical_BP.jpg
Logo:
https://mma.prnewswire.com/media/2270774/Recor_Medical_Logo.jpg
View original content to download
multimedia:https://www.prnewswire.com/news-releases/recor-medical-champions-global-action-on-world-hypertension-day-early-intervention-and-continued-innovation-crucial-in-tackling-this-silent-killer-impacting-billions-worldwide-302148369.html
SOURCE Recor Medical Inc.